文献速递心力衰竭与心肌病

射血分数轻度降低或保留的心力衰竭中研究者报告的室性心律失常与死亡率

Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction.
PubMed 文献 · Eur Heart J · 2023-01-01

本研究合并PARAGON-HF、TOPCAT、I-Preserve和CHARM-Preserved四项试验数据,分析HFmrEF和HFpEF患者中研究者报告的室速/室颤(VT/VF)发生率及其与死亡的关系。VT/VF与全因死亡(调整HR 3.95,95%CI 2.80-5.57;P<0.001)和心血管死亡相关,主要由心衰死亡驱动而非猝死。HFmrEF患者VT/VF发生率高于HFpEF(调整HR 2.19,95%CI 1.77-2.71)。

要点

  • HFmrEF和HFpEF患者中VT/VF不常见,发生率0.3/100人年。
  • VT/VF与全因死亡强烈相关(调整HR 3.95),但主要由心衰死亡驱动而非猝死。
  • HFmrEF患者VT/VF发生率高于HFpEF(调整HR 2.19)。

核心结论

  • VT/VF在HFmrEF和HFpEF患者中不常见,但与死亡率强烈相关,似乎是疾病严重程度的标志而非猝死风险。

研究设计与样本

  • VT/VF为研究者报告的不良事件,采用时间更新Cox比例风险回归模型分析其与死亡的关系。

主要发现

  • 146例(1.1%)发生VT/VF,发生率0.3/100人年。
  • 发生VT/VF的患者更可能为男性、有心肌梗死史、肾功能较差、左心室重构更 adverse、NT-proBNP更高。
  • VT/VF与全因死亡相关(调整HR 3.95,95%CI 2.80-5.57;P<0.001),也与心血管死亡相关,由心衰死亡驱动而非猝死。
  • HFmrEF患者VT/VF发生率高于HFpEF(调整HR 2.19,95%CI 1.77-2.71)。
  • 与VT/VF相关的变量包括NT-proBNP、房颤/房扑史、男性、较低射血分数和高血压史。

临床怎么用

  • 在HFmrEF和HFpEF患者中,发生VT/VF应视为疾病严重程度标志,需关注心衰进展和死亡风险。
  • VT/VF与心衰死亡而非猝死驱动相关,提示优化心衰治疗可能比单纯抗心律失常更重要。

局限性

  • VT/VF为研究者报告的不良事件,可能存在漏报或误报。
  • 数据来源于四项临床试验的合并分析,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Few reports have examined the incidence of ventricular tachycardia (VT) and ventricular fibrillation (VF) or their relationship with mortality in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: Data from the PARAGON-HF, TOPCAT, I-Preserve, and CHARM-Preserved trials were merged. VT/VF, reported as adverse events, were identified. Patients who experienced VT/VF were compared with patients who did not. The relationship between VT/VF and mortality was examined in time-updated Cox proportional hazard regression models. Variables associated with VT/VF were examined in Cox proportional hazard regression models. The rate of VT/VF in patients with HFmrEF compared with patients with HFpEF was examined in a Cox proportional hazards regression model. Of 13 609 patients, over a median follow-up of 1170 days (interquartile range: 966-1451), 146 (1.1%) experienced an investigator-reported VT/VF (incidence rate 0.3 per 100 person-years). Patients who experienced VT/VF were more likely to be male, have had a myocardial infarction, poorer renal function, more adverse left ventricular remodelling, and higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) than patients who did not. Occurrence of VT/VF was associated with NT-proBNP, history of atrial fibrillation/flutter, male sex, lower ejection fraction, and history of hypertension. VT/VF was associated with all-cause death [adjusted hazard ratio (HR): 3.95, 95% confidence interval (CI): 2.80-5.57; P < 0.001] and cardiovascular death, driven by death from heart failure and not sudden death. Patients with HFmrEF had a higher rate of VT/VF than patients with HFpEF (adjusted HR: 2.19, 95% CI: 1.77-2.71). CONCLUSION: VT/VF was uncommon in patients with HFmrEF and HFpEF. However, such events were strongly associated with mortality and appear to be a marker of disease severity rather than risk of sudden death. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov unique identifier: NCT01920711(PARAGON-HF); NCT00094302 (TOPCAT); NCT00095238 (I-Preserve); NCT00634712 (CHARM-Preserved).

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Curtain, Adamson, Kondo, et al. Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. Eur Heart J. 2023. PMID: 36632831. doi:10.1093/eurheartj/ehac801

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。